EC Number   |
Title |
Organism |
|---|
   3.4.17.20 | Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different invitro models |
Homo sapiens |
| 3.4.17.20 | Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis |
Homo sapiens |
| 3.4.17.20 | Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis |
Homo sapiens |
| 3.4.17.20 | Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction |
Homo sapiens |
| 3.4.17.20 | A new functional assay of thrombin activatable fibrinolysis inhibitor |
Homo sapiens |
| 3.4.17.20 | Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels |
Homo sapiens |
| 3.4.17.20 | Activation and characterization of procarboxypeptidase B from human plasma |
Homo sapiens |
| 3.4.17.20 | Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C |
Homo sapiens |
| 3.4.17.20 | Active carboxypeptidase B is present in free form in serum from patients with acute pancreatitis |
Homo sapiens |
| 3.4.17.20 | Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation |
Homo sapiens |
